Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) to a strong-buy rating in a report released on Tuesday, Zacks.com reports.

A number of other brokerages also recently weighed in on QNCX. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a "strong-buy" rating in a report on Tuesday, October 22nd. Rodman & Renshaw began coverage on shares of Quince Therapeutics in a report on Tuesday. They set a "buy" rating and a $11.00 target price on the stock.

Quince Therapeutics Stock Up 11.0 %

Shares of QNCX stock traded up $0.13 during trading on Tuesday, reaching $1.31. The company's stock had a trading volume of 12,478,205 shares, compared to its average volume of 209,985. The business has a fifty day moving average price of $0.77 and a 200-day moving average price of $0.80. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.29. The company has a market cap of $56.61 million, a price-to-earnings ratio of -1.55 and a beta of 0.86. Quince Therapeutics has a one year low of $0.51 and a one year high of $1.79.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter.

Insider Buying and Selling at Quince Therapeutics

In related news, President Charles S. Ryan acquired 48,387 shares of the firm's stock in a transaction on Tuesday, August 20th. The shares were purchased at an average cost of $0.65 per share, for a total transaction of $31,451.55. Following the completion of the acquisition, the president now directly owns 122,461 shares in the company, valued at approximately $79,599.65. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, President Charles S. Ryan acquired 48,387 shares of the firm's stock in a transaction on Tuesday, August 20th. The shares were purchased at an average cost of $0.65 per share, for a total transaction of $31,451.55. Following the completion of the acquisition, the president now directly owns 122,461 shares in the company, valued at approximately $79,599.65. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Dirk Thye acquired 77,500 shares of the firm's stock in a transaction on Thursday, August 29th. The stock was purchased at an average cost of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the acquisition, the chief executive officer now owns 766,941 shares in the company, valued at approximately $529,189.29. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 158,887 shares of company stock worth $105,609 over the last ninety days. Insiders own 16.80% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.